Charlotte’s Web Holdings ( (TSE:CWEB) ) has provided an announcement.
On February 24, 2025, Charlotte’s Web Holdings announced that the FDA has approved DeFloria, Inc., a company in which it holds a minority interest, to proceed with Phase 2 clinical trials for AJA001 Oral Solution, a treatment for autism spectrum disorder. This development marks a significant milestone in botanical drug development, leveraging Charlotte’s Web’s expertise in hemp cultivation to potentially provide a new treatment option for ASD, thus extending its leadership from consumer wellness into the regulated medical sector.
More about Charlotte’s Web Holdings
Charlotte’s Web Holdings, Inc., headquartered in Louisville, Colorado, is a market leader in hemp extract wellness products. The company offers a range of products including CBD oil tinctures, gummies, capsules, topical creams, and pet products, all derived from proprietary hemp genetics cultivated using organic and regenerative practices. Charlotte’s Web products are distributed throughout the U.S. and online, and the company is the official CBD partner of Major League Baseball.
YTD Price Performance: -3.96%
Average Trading Volume: 246,079
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.58M
For detailed information about CWEB stock, go to TipRanks’ Stock Analysis page.